Business article - August 25, 2026
Q&A: Simon Fredriksson, CEO and Co-founder, Pixelgen
NLS asked the CEO and co-founder of Pixelgen about entrepreneurship in Sweden, the company's global commercialization strategy and the most exciting clinical applications of the company's Proxiome kit.
Science News - August 25, 2026
Turku researchers uncover molecular mechanism behind aggressive colorectal cancer
Researchers at the University of Turku, working with France's Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.
In a new job - August 25, 2026
ALK-Abelló appoints new head of Global R&D
ALK-Abelló has appointed Jacob Glenting as Executive Vice President and head of Global R&D, effective 1 September.
Pharma Business - August 25, 2026
FDA proposes reclassifying Photocure’s blue light cystoscopy systems
The US FDA has proposed reclassifying blue light cystoscopy (BLC) systems used with Photocure's imaging agent Cysview for bladder cancer detection from Class III to Class II, a move the Norwegian medtech company says will support wider adoption of the technology in US hospitals.
New Market - August 24, 2026
Genetic Analysis enters Australian market
Norwegian microbiome diagnostics company Genetic Analysis has placed its GA-map Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney – the company's first placement in Australia and a new milestone in its international expansion.
Biotech Business - August 24, 2026
Nykode secures new US patent for cancer vaccine candidate
Nykode Therapeutics has been granted a new US patent covering its individualized neoantigen cancer vaccine VB10.NEO and related modular vaccine designs, strengthening the company's intellectual property position as the neoantigen vaccine field gains momentum.
